Anh Tu Nguyen - 25 Feb 2025 Form 3 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Medical Officer
Signature
/s/ Beth Hecht, Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
25 Feb 2025
Net transactions value
$0
Form type
3
Filing time
07 Mar 2025, 16:11:06 UTC
Next filing
02 Feb 2026
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding XERS Common Stock 300,000 25 Feb 2025 Direct F1
holding XERS Common Stock 3,710 25 Feb 2025 By IRA F2
holding XERS Common Stock 3,501 25 Feb 2025 By children's IRA F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding XERS Stock Appreciation Right 25 Feb 2025 Common Stock 150,000 $3.76 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
F2 The shares were acquired through a custodial account established for the Reporting Person's children for which the Reporting Person serves as a custodian.
F3 This stock appreciation right granted under the Company's 2018 Stock Option and Incentive Plan will vest in full on the second anniversary of the February 24, 2025 grant date, subject to continued service with the company through the vesting date.
F4 Upon exercise, the stock appreciation right will be settled in cash.

Remarks:

Chief Medical Officer